Loading...

Allen C Gao

TitleProfessor
InstitutionUniversity of California Davis
DepartmentUrology
Address4645 2nd Ave
CA 95817
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Novel mechanisms of resistance to antiandrogen therapies
    VA I01BX004036Jul 1, 2018 - Jun 30, 2022
    Role: Principal Investigator
    Omics in Urologic Research-New Frontiers Driving Precision Medicine
    NIH/NIDDK R13DK104455Sep 8, 2014 - Aug 31, 2015
    Role: Principal Investigator
    The role of p52 in prostate cancer
    VA I01BX002653Jul 1, 2014 - Jun 30, 2018
    Role: Principal Investigator
    (PQD-1) NF-kB activation and enzalutamide therapy in metastatic castration resist
    NIH/NCI R21CA179970Sep 12, 2013 - Aug 31, 2015
    Role: Principal Investigator
    Novel roles of microRNA in androgen receptor signaling
    NIH/NCI R01CA168601Apr 1, 2013 - Mar 31, 2018
    Role: Principal Investigator
    Role of Rho GDP dissociation inhibitors in androgen signaling in prostate cancer
    VA I01BX000526Apr 1, 2010 - Mar 31, 2015
    Role: Principal Investigator
    Interleukin-6 and castration-resistant prostate cancer
    NIH/NCI R01CA140468Apr 1, 2010 - Feb 28, 2015
    Role: Principal Investigator
    Selenium regulates androgen receptor signaling in prostate cancer
    NIH/NCI R01CA118887Mar 6, 2006 - Jul 31, 2012
    Role: Principal Investigator
    IL-4 and androgen receptor signaling in prostate cancer
    NIH/NCI R01CA109441Apr 1, 2005 - Feb 29, 2012
    Role: Principal Investigator
    Stat3 in Androgen Receptor Signaling in Prostate Cancer
    NIH/NCI R01CA090271Jul 20, 2001 - May 31, 2007
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Wang HJ, Pochampalli M, Wang LY, Zou JX, Li PS, Hsu SC, Wang BJ, Huang SH, Yang P, Yang JC, Chu CY, Hsieh CL, Sung SY, Li CF, Tepper CG, Ann DK, Gao AC, Evans CP, Izumiya Y, Chuu CP, Wang WC, Chen HW, Kung HJ. KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC. Oncogene. 2018 Aug 02. PMID: 30072740.
      View in: PubMed
    2. Lombard AP, Liu L, Cucchiara V, Liu C, Armstrong CM, Zhao R, Yang JC, Lou W, Evans CP, Gao AC. Intra vs Inter Cross-Resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer. Mol Cancer Ther. 2018 Jun 11. PMID: 29891490.
      View in: PubMed
    3. Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol. 2018 May; 73(5):715-723. PMID: 29258679.
      View in: PubMed
    4. Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. J Natl Cancer Inst. 2017 Dec 01; 109(12). PMID: 29206995.
      View in: PubMed
    5. Tummala R, Lou W, Gao AC, Nadiminty N. Quercetin Targets hnRNPA1 to Overcome Enzalutamide Resistance in Prostate Cancer Cells. Mol Cancer Ther. 2017 Dec; 16(12):2770-2779. PMID: 28729398.
      View in: PubMed
    6. Lombard AP, Liu C, Armstrong CM, Cucchiara V, Gu X, Lou W, Evans CP, Gao AC. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer. Mol Cancer Ther. 2017 Oct; 16(10):2257-2266. PMID: 28698198.
      View in: PubMed
    7. Recouvreux MV, Wu JB, Gao AC, Zonis S, Chesnokova V, Bhowmick N, Chung LW, Melmed S. Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells. Endocrinology. 2017 07 01; 158(7):2255-2268. PMID: 28444169.
      View in: PubMed
    8. Armstrong CM, Liu C, Lou W, Lombard AP, Evans CP, Gao AC. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells. Prostate. 2017 Jun; 77(9):1020-1028. PMID: 28485104.
      View in: PubMed
    9. Liu C, Armstrong CM, Lou W, Lombard AP, Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP, Gao AC. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer. Mol Cancer Ther. 2017 Aug; 16(8):1521-1530. PMID: 28500234.
      View in: PubMed
    10. Armstrong CM, Gao AC. CCN3-EZH2-AR feedback loop: new targets for enzalutamide and castration resistant prostate cancer. J Cell Commun Signal. 2017 Mar; 11(1):89-91. PMID: 28255661.
      View in: PubMed
    11. Cucchiara V, Yang JC, Mirone V, Gao AC, Rosenfeld MG, Evans CP. Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy. Cancers (Basel). 2017 Jan 16; 9(1). PMID: 28275218.
      View in: PubMed
    12. Liu C, Armstrong CM, Lou W, Lombard A, Evans CP, Gao AC. Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer. Mol Cancer Ther. 2017 01; 16(1):35-44. PMID: 27794047.
      View in: PubMed
    13. Armstrong CM, Gao AC. Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer. Asian J Urol. 2016 Oct; 3(4):185-194. PMID: 28642838.
      View in: PubMed
    14. Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, Gao AC, Evans CP, Lam KS, Xu J, Kung HJ, Evans RM, Xu Y, Chen HW. Corrigendum: ROR-? drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med. 2016 06 07; 22(6):692. PMID: 27270780.
      View in: PubMed
    15. Liu C, Armstrong C, Zhu Y, Lou W, Gao AC. Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. Oncotarget. 2016 May 31; 7(22):32210-20. PMID: 27049719.
      View in: PubMed
    16. Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, Gao AC, Evans CP, Lam KS, Xu J, Kung HJ, Evans RM, Xu Y, Chen HW. ROR-? drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med. 2016 05; 22(5):488-96. PMID: 27019329; PMCID: PMC5030109.
    17. Tummala R, Nadiminty N, Lou W, Evans CP, Gao AC. Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation. Prostate. 2016 Apr; 76(5):445-55. PMID: 26714839.
      View in: PubMed
    18. Chandrasekar T, Yang JC, Gao AC, Evans CP. Targeting molecular resistance in castration-resistant prostate cancer. BMC Med. 2015 Sep 01; 13:206. PMID: 26329698; PMCID: PMC4556222.
    19. Armstrong CM, Gao AC. Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. Am J Clin Exp Urol. 2015; 3(2):64-76. PMID: 26309896; PMCID: PMC4539108.
    20. Gao AC, Zhu Y. Stat5a/b in Prostate Cancer Metastasis. Am J Pathol. 2015 Sep; 185(9):2351-3. PMID: 26187549.
      View in: PubMed
    21. Nadiminty N, Tummala R, Liu C, Lou W, Evans CP, Gao AC. NF-?B2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer. Mol Cancer Ther. 2015 Aug; 14(8):1884-95. PMID: 26056150; PMCID: PMC4529751.
    22. Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015 Jun; 4(3):365-80. PMID: 26814148; PMCID: PMC4708226.
    23. Zhu Y, Liu C, Armstrong C, Lou W, Sandher A, Gao AC. Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer. Clin Cancer Res. 2015 Sep 15; 21(18):4133-42. PMID: 25995342; PMCID: PMC4573793.
    24. Liu C, Lou W, Armstrong C, Zhu Y, Evans CP, Gao AC. Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition. Prostate. 2015 Sep; 75(13):1341-53. PMID: 25970160; PMCID: PMC4536195.
    25. Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW, Evans CP, Gao AC. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. Cancer Res. 2015 Apr 01; 75(7):1413-22. PMID: 25649766; PMCID: PMC4383695.
    26. Ghosh PM, Gao AC. Zoledronic acid at the time of castration prevented castration-induced bone metastasis in mice. Endocr Relat Cancer. 2014 Oct; 21(5):C11-4. PMID: 25183429.
      View in: PubMed
    27. Zhu Y, Liu C, Cui Y, Nadiminty N, Lou W, Gao AC. Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST). Prostate. 2014 Aug; 74(11):1086-94. PMID: 24819501.
      View in: PubMed
    28. Cui Y, Nadiminty N, Liu C, Lou W, Schwartz CT, Gao AC. Upregulation of glucose metabolism by NF-?B2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells. Endocr Relat Cancer. 2014 Jun; 21(3):435-42. PMID: 24659479; PMCID: PMC4021715.
    29. Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res. 2014 Jun 15; 20(12):3198-3210. PMID: 24740322; PMCID: PMC4058390.
    30. Qu S, Wang K, Xue H, Wang Y, Wu R, Liu C, Gao AC, Gout PW, Collins CC, Wang Y. Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model. Mol Oncol. 2014 Mar; 8(2):311-22. PMID: 24388358.
      View in: PubMed
    31. Liu C, Zhu Y, Lou W, Cui Y, Evans CP, Gao AC. Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. Prostate. 2014 Feb; 74(2):201-9. PMID: 24307657; PMCID: PMC4437226.
    32. Zhu Y, Liu C, Tummala R, Nadiminty N, Lou W, Gao AC. RhoGDIa downregulates androgen receptor signaling in prostate cancer cells. Prostate. 2013 Nov; 73(15):1614-22. PMID: 23922223; PMCID: PMC3941975.
    33. Zhu Y, Liu C, Nadiminty N, Lou W, Tummala R, Evans CP, Gao AC. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Mol Cancer Ther. 2013 Sep; 12(9):1829-36. PMID: 23861346; PMCID: PMC3947549.
    34. Tummala R, Nadiminty N, Lou W, Zhu Y, Gandour-Edwards R, Chen HW, Evans CP, Gao AC. Lin28 promotes growth of prostate cancer cells and activates the androgen receptor. Am J Pathol. 2013 Jul; 183(1):288-95. PMID: 23790802; PMCID: PMC3702743.
    35. Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, Gao AC. NF-?B2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther. 2013 Aug; 12(8):1629-37. PMID: 23699654; PMCID: PMC3941973.
    36. Duan Z, Zou JX, Yang P, Wang Y, Borowsky AD, Gao AC, Chen HW. Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex. Prostate. 2013 Apr; 73(5):455-66. PMID: 23038103.
      View in: PubMed
    37. Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, Shi XB, deVere White RW, Gao AC. Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate. 2013 Mar; 73(4):418-27. PMID: 22996738; PMCID: PMC3938015.
    38. Yang P, Guo L, Duan ZJ, Tepper CG, Xue L, Chen X, Kung HJ, Gao AC, Zou JX, Chen HW. Histone methyltransferase NSD2/MMSET mediates constitutive NF-?B signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol. 2012 Aug; 32(15):3121-31. PMID: 22645312; PMCID: PMC3434505.
    39. Nadiminty N, Tummala R, Lou W, Zhu Y, Shi XB, Zou JX, Chen H, Zhang J, Chen X, Luo J, deVere White RW, Kung HJ, Evans CP, Gao AC. MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS One. 2012; 7(3):e32832. PMID: 22479342; PMCID: PMC3316551.
    40. Ge D, Gao AC, Zhang Q, Liu S, Xue Y, You Z. LNCaP prostate cancer cells with autocrine interleukin-6 expression are resistant to IL-6-induced neuroendocrine differentiation due to increased expression of suppressors of cytokine signaling. Prostate. 2012 Sep 01; 72(12):1306-16. PMID: 22213096; PMCID: PMC3665156.
    41. Nadiminty N, Tummala R, Lou W, Zhu Y, Zhang J, Chen X, eVere White RW, Kung HJ, Evans CP, Gao AC. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem. 2012 Jan 06; 287(2):1527-37. PMID: 22128178; PMCID: PMC3256915.
    42. Zhong X, Li L, Wang M, Luo W, Tan Q, Xu F, Zhu W, Wang Q, Wang T, Hou M, Nadimity N, Xue X, Chen J, Ma W, Gao AC, Zhou Q. A proteomic approach to elucidate the multiple targets of selenium-induced cell-growth inhibition in human lung cancer. Thorac Cancer. 2011 Nov; 2(4):164-178. PMID: 27755845.
      View in: PubMed
    43. Nadiminty N, Gao AC. Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives. World J Urol. 2012 Jun; 30(3):287-95. PMID: 22009116.
      View in: PubMed
    44. Libertini SJ, Chen H, al-Bataina B, Koilvaram T, George M, Gao AC, Mudryj M. The interleukin 6 receptor is a direct transcriptional target of E2F3 in prostate tumor derived cells. Prostate. 2012 May 01; 72(6):649-60. PMID: 21837779.
      View in: PubMed
    45. Zhu Y, Tummala R, Liu C, Nadiminty N, Lou W, Evans CP, Zhou Q, Gao AC. RhoGDIa suppresses growth and survival of prostate cancer cells. Prostate. 2012 Mar; 72(4):392-8. PMID: 21681778; PMCID: PMC3961824.
    46. Sun M, Liu C, Nadiminty N, Lou W, Zhu Y, Yang J, Evans CP, Zhou Q, Gao AC. Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion. Prostate. 2012 Jan; 72(1):82-9. PMID: 21538419; PMCID: PMC3938016.
    47. Liu C, Liu H, Li Y, Wu Z, Zhu Y, Wang T, Gao AC, Chen J, Zhou Q. Intracellular glutathione content influences the sensitivity of lung cancer cell lines to methylseleninic acid. Mol Carcinog. 2012 Apr; 51(4):303-14. PMID: 21520298.
      View in: PubMed
    48. Liu C, Nadiminty N, Tummala R, Chun JY, Lou W, Zhu Y, Sun M, Evans CP, Zhou Q, Gao AC. Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer. Genes Cancer. 2011 Feb; 2(2):151-9. PMID: 21779488; PMCID: PMC3111248.
    49. Duleba AJ, Ahmed MI, Sun M, Gao AC, Villanueva J, Conley AJ, Turgeon JL, Benirschke K, Gee NA, Chen J, Green PG, Lasley BL. Effects of triclocarban on intact immature male rat: augmentation of androgen action. Reprod Sci. 2011 Feb; 18(2):119-27. PMID: 20889956; PMCID: PMC3031453.
    50. Yang X, You J, Luo W, Yue J, Ma L, Xiao W, Zhu D, Wu Z, Wang D, Nadiminty N, Gao AC, Zhou Q. The N-terminal kinase suppressor of Ras complex has a weak nucleoside diphosphate kinase activity. Thorac Cancer. 2010 09; 1(3):109-115. PMID: 27755802.
      View in: PubMed
    51. Chun JY, Tummala R, Nadiminty N, Lou W, Liu C, Yang J, Evans CP, Zhou Q, Gao AC. Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth. Genes Cancer. 2010 Aug; 1(8):868-76. PMID: 21442031; PMCID: PMC3063649.
    52. Yang JC, Bai L, Yap S, Gao AC, Kung HJ, Evans CP. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model. Mol Cancer Ther. 2010 Jun; 9(6):1629-37. PMID: 20484016.
      View in: PubMed
    53. Nadiminty N, Lou W, Sun M, Chen J, Yue J, Kung HJ, Evans CP, Zhou Q, Gao AC. Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res. 2010 Apr 15; 70(8):3309-19. PMID: 20388792; PMCID: PMC3041633.
    54. Sun M, Lou W, Chun JY, Cho DS, Nadiminty N, Evans CP, Chen J, Yue J, Zhou Q, Gao AC. Sanguinarine suppresses prostate tumor growth and inhibits survivin expression. Genes Cancer. 2010 Mar; 1(3):283-92. PMID: 21318089; PMCID: PMC3036540.
    55. Nadiminty N, Dutt S, Tepper C, Gao AC. Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells. Prostate. 2010 Feb 15; 70(3):276-87. PMID: 19827050.
      View in: PubMed
    56. Dutt SS, Gao AC. Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol. 2009 Nov; 5(9):1403-13. PMID: 19903068; PMCID: PMC3041149.
    57. Chun JY, Nadiminty N, Dutt S, Lou W, Yang JC, Kung HJ, Evans CP, Gao AC. Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res. 2009 Aug 01; 15(15):4815-22. PMID: 19638459; PMCID: PMC3041150.
    58. Feng S, Tang Q, Sun M, Chun JY, Evans CP, Gao AC. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther. 2009 Mar; 8(3):665-71. PMID: 19240160; PMCID: PMC3041173.
    59. Lee SO, Chun JY, Nadiminty N, Lou W, Feng S, Gao AC. Interleukin-4 activates androgen receptor through CBP/p300. Prostate. 2009 Feb 01; 69(2):126-32. PMID: 18819102; PMCID: PMC3035998.
    60. Nadiminty N, Chun JY, Lou W, Lin X, Gao AC. NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation. Prostate. 2008 Dec 01; 68(16):1725-33. PMID: 18781579.
      View in: PubMed
    61. Nadiminty N, Gao AC. Mechanisms of selenium chemoprevention and therapy in prostate cancer. Mol Nutr Food Res. 2008 Nov; 52(11):1247-60. PMID: 18727008.
      View in: PubMed
    62. Hu Y, Sun M, Nadiminty N, Lou W, Pinder E, Gao AC. Transcriptional regulation of human RANK ligand gene expression by E2F1. Biochem Biophys Res Commun. 2008 Jun 06; 370(3):440-4. PMID: 18381203; PMCID: PMC2950805.
    63. Lee SO, Pinder E, Chun JY, Lou W, Sun M, Gao AC. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. Prostate. 2008 Jan 01; 68(1):85-91. PMID: 18008330.
      View in: PubMed
    64. Chun JY, Hu Y, Pinder E, Wu J, Li F, Gao AC. Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Mol Cancer Ther. 2007 Sep; 6(9):2572-80. PMID: 17876054; PMCID: PMC2821810.
    65. Lee SO, Dutt SS, Nadiminty N, Pinder E, Liao H, Gao AC. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line. Prostate. 2007 Sep 01; 67(12):1293-300. PMID: 17626246.
      View in: PubMed
    66. Nadiminty N, Chun JY, Hu Y, Dutt S, Lin X, Gao AC. LIGHT, a member of the TNF superfamily, activates Stat3 mediated by NIK pathway. Biochem Biophys Res Commun. 2007 Jul 27; 359(2):379-84. PMID: 17543278; PMCID: PMC2062522.
    67. Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate. 2007 May 15; 67(7):764-73. PMID: 17373716.
      View in: PubMed
    68. Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, Gao AC. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate. 2006 Jul 01; 66(10):1070-5. PMID: 16637076.
      View in: PubMed
    69. Park SY, Kim YJ, Gao AC, Mohler JL, Onate SA, Hidalgo AA, Ip C, Park EM, Yoon SY, Park YM. Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer Res. 2006 May 15; 66(10):5121-9. PMID: 16707435.
      View in: PubMed
    70. Nadiminty N, Lou W, Lee SO, Lin X, Trump DL, Gao AC. Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation. Proc Natl Acad Sci U S A. 2006 May 09; 103(19):7264-9. PMID: 16651533; PMCID: PMC1464331.
    71. Chun JY, Nadiminty N, Lee SO, Onate SA, Lou W, Gao AC. Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer. Mol Cancer Ther. 2006 Apr; 5(4):913-8. PMID: 16648561.
      View in: PubMed
    72. Nadiminty N, Lou W, Lee SO, Mehraein-Ghomi F, Kirk JS, Conroy JM, Zhang H, Gao AC. Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2. Clin Cancer Res. 2006 Mar 01; 12(5):1420-30. PMID: 16533764.
      View in: PubMed
    73. Tan D, Wu X, Hou M, Lee SO, Lou W, Wang J, Janarthan B, Nallapareddy S, Trump DL, Gao AC. Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol. 2005 Aug; 174(2):753-6. PMID: 16006970.
      View in: PubMed
    74. Dong Y, Zhang H, Gao AC, Marshall JR, Ip C. Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers. Mol Cancer Ther. 2005 Jul; 4(7):1047-55. PMID: 16020662.
      View in: PubMed
    75. Lee SO, Lou W, Nadiminty N, Lin X, Gao AC. Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate. 2005 Jul 01; 64(2):160-7. PMID: 15678501.
      View in: PubMed
    76. Lee SO, Nadiminty N, Wu XX, Lou W, Dong Y, Ip C, Onate SA, Gao AC. Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells. Cancer Res. 2005 Apr 15; 65(8):3487-92. PMID: 15833885.
      View in: PubMed
    77. Lee SO, Lou W, Qureshi KM, Mehraein-Ghomi F, Trump DL, Gao AC. RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate. 2004 Sep 01; 60(4):303-9. PMID: 15264241.
      View in: PubMed
    78. Lee SO, Lou W, Johnson CS, Trump DL, Gao AC. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate. 2004 Aug 01; 60(3):178-86. PMID: 15176047.
      View in: PubMed
    79. Dong Y, Lee SO, Zhang H, Marshall J, Gao AC, Ip C. Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res. 2004 Jan 01; 64(1):19-22. PMID: 14729601.
      View in: PubMed
    80. Gao AC, Lou W, Dong JT, Barrett JC, Danielpour D, Isaacs JT. Defining regulatory elements in the human KAI1 (CD 82) metastasis suppressor gene. Prostate. 2003 Dec 01; 57(4):256-60. PMID: 14601021.
      View in: PubMed
    81. Lee SO, Lou W, Hou M, Onate SA, Gao AC. Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene. 2003 Sep 11; 22(39):7981-8. PMID: 12970746.
      View in: PubMed
    82. Leman ES, DeMiguel F, Gao AC, Getzenberg RH. Regulation of androgen and vitamin d receptors by 1,25-dihydroxyvitamin D3 in human prostate epithelial and stromal cells. J Urol. 2003 Jul; 170(1):235-40. PMID: 12796696.
      View in: PubMed
    83. Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, Xie K. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene. 2003 Jan 23; 22(3):319-29. PMID: 12545153.
      View in: PubMed
    84. Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res. 2003 Jan; 9(1):370-6. PMID: 12538490.
      View in: PubMed
    85. DeMiguel F, Lee SO, Lou W, Xiao X, Pflug BR, Nelson JB, Gao AC. Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice. Prostate. 2002 Jul 01; 52(2):123-9. PMID: 12111703.
      View in: PubMed
    86. Dhir R, Ni Z, Lou W, DeMiguel F, Grandis JR, Gao AC. Stat3 activation in prostatic carcinomas. Prostate. 2002 Jun 01; 51(4):241-6. PMID: 11987152.
      View in: PubMed
    87. Ni Z, Lou W, Lee SO, Dhir R, DeMiguel F, Grandis JR, Gao AC. Selective activation of members of the signal transducers and activators of transcription family in prostate carcinoma. J Urol. 2002 Apr; 167(4):1859-62. PMID: 11912448.
      View in: PubMed